Amydis Overview

  • Year Founded
  • 2013

Year Founded

  • Status
  • Private

  • Employees
  • 9

Employees

  • Latest Deal Type
  • Series A2

  • Latest Deal Amount
  • $6M

  • Investors
  • 3

Amydis General Information

Description

Developer of a new class of diagnostic compounds intended to revolutionize the early detection and treatment of neurodegenerative diseases, as well as the clinical evaluation of novel therapeutics. The company develops novel, patent-protected small molecule ocular tracers, which enable direct visualization of retinal disease-related molecular changes (biomarkers) in the eye, enabling healthcare professionals to identify disorders that involve the presence of amyloid proteins for targeting the detection of early-stage Alzheimer's and other amyloid-associated diseases.

Contact Information

Website
www.amydis.com
Formerly Known As
Amydis Diagnostics
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Primary Office
  • 1800 Century Park East
  • Suite 600
  • Los Angeles, CA 90067
  • United States
+1 (310) 000-0000

Amydis Timeline

2020202120222023
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Amydis Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
11. Later Stage VC (Series A2) 29-Dec-2022 $6M 000.00 0000 Completed Generating Revenue
10. Grant 27-Oct-2022 00.000 00.000 Completed Generating Revenue
9. Later Stage VC (Series A) 21-Apr-2022 00.000 00.000 000.00 Completed Generating Revenue
8. Grant 23-Sep-2021 00.000 Completed Generating Revenue
7. Grant 01-Sep-2021 00000 Completed Generating Revenue
6. Grant 10-Aug-2021 00.00 Completed Generating Revenue
5. Grant 01-Jun-2021 00.000 Completed Generating Revenue
4. Grant 23-Sep-2019 00.00 Completed Generating Revenue
3. Early Stage VC 01-Jan-2017 Completed Generating Revenue
2. Accelerator/Incubator 01-Jan-2016 Completed Generating Revenue
To view Amydis’s complete valuation and funding history, request access »

Amydis Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series A2 0,000,000 00.000000 00 00.00 00.00 00 00.00 000
Series A 0,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
To view Amydis’s complete cap table history, request access »

Amydis Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of a new class of diagnostic compounds intended to revolutionize the early detection and treatment of neurodeg
Biotechnology
Los Angeles, CA
9 As of 2023
000.00
000 0000-00-00
00000000000 000.00

000000

m dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt
0000 000000000
New York, NY
00 As of 0000
00000
0000 0000-00-00
00000000000 00000

000 00

ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in vo
0000 000000000
Barcelona, Spain
00 As of 0000
0000
00000000000 0000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Amydis Competitors (13)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Volastra Venture Capital-Backed New York, NY 00 00000 00000000000 00000
000 000000000000 Venture Capital-Backed Barcelona, Spain 00 0000 00000000000 0000
00 000000000000 Formerly VC-backed Durham, NC 000 00000 00000000 00000
000000000 000000 Venture Capital-Backed Burlington, MA 00 00000 00000000000 00000
0000000 000000 Venture Capital-Backed Stockholm, Sweden 00 000.00 0000000000 0 000.00
You’re viewing 5 of 13 competitors. Get the full list »

Amydis Patents

  • 21

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 000

    Granted

  • 5

    Pending

  • 000

    Expiring in next 12 mo

Amydis Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2022234434-A1 Methods of detecting systemic amyloidosis via binding to misfolded or aggregated protein Pending 12-Mar-2021 00000000000
CA-3212704-A1 Methods of detecting systemic amyloidosis via binding to misfolded or aggregated protein Pending 12-Mar-2021
AU-2020348382-A1 Methods of detecting neurological disorders via binding to phosphorylated tau protein Pending 18-Sep-2019 00000000000
CA-3154481-A1 Methods of detecting neurological disorders via binding to phosphorylated tau protein Pending 18-Sep-2019 00000000000
EP-4031879-A1 Methods of detecting neurological disorders via binding to phosphorylated tau protein Pending 18-Sep-2019 A61K49/0021
To view Amydis’s complete patent history, request access »

Amydis Executive Team (12)

Name Title Board Seat Contact Info
Jack Thrift Chief Financial Officer
Ali Tafreshi Chief Technology Officer
Jerry Yang Ph.D Co-Founder & Chief Scientific Officer
Robert Weinreb MD Chairman of Scientific Advisory Board
Ron Newbold Ph.D Chief Business Officer
You’re viewing 5 of 12 executive team members. Get the full list »

Amydis Board Members (9)

Name Representing Role Since
Christine Aylward Self Board Member 000 0000
Faith Charles JD Self Board Member 000 0000
Franz Hefti Ph.D Self Board Member 000 0000
James Khodabakhsh MD Self Board Member 000 0000
Jerre Stead Self Board Member 000 0000
You’re viewing 5 of 9 board members. Get the full list »

Amydis Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Amydis Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Michael J. Fox Foundation Limited Partner 000 0000 000000 0
Springboard Enterprises Accelerator/Incubator 000 0000 000000 0
Johnson & Johnson Innovation - JLABS Accelerator/Incubator 000 0000 000000 0
To view Amydis’s complete investors history, request access »

Ready to get started?

Request a free trial